Foxo3 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
FOXO3 (Forkhead Box O3) is a transcription factor belonging to the Forkhead box (Fox) family of winged-helix DNA-binding proteins. It is a key regulator of cellular stress response, longevity, apoptosis, and metabolic homeostasis. FOXO3 is widely expressed in neurons throughout the brain and plays critical roles in neuroprotection against various stressors including oxidative stress, proteotoxic stress, and mitochondrial dysfunction. Genetic variants of FOXO3 have been associated with human longevity and increased risk for several neurodegenerative diseases.
| Property |
Value |
| Symbol |
FOXO3 |
| Full Name |
Forkhead Box O3 |
| Chromosomal Location |
6q21 |
| NCBI Gene ID |
2309 |
| OMIM |
602786 |
| Ensembl ID |
ENSG00000118445 |
| UniProt ID |
Q9Y5X3 |
| Gene Type |
Protein coding |
| Transcript Size |
~40 kb |
| Exon Count |
4 exons |
- FKHR-L1 (Forkhead Homolog in Rhabdomyosarcoma-Like 1)
- FOXO3A
- AF6q21
- MLLT7 (Mixed Lineage Leukemia Translocation to Chromosome 7)
The FOXO3 promoter contains several key regulatory elements:
- Stress response elements (SRE): Respond to oxidative stress and DNA damage
- FOXO response elements (FHRE): Canonical binding sites (GTAAACAA)
- SIRT1 binding site: SIRT1 deacetylates FOXO3 for activation
- p53 binding region: Cross-talk with p53 tumor suppressor pathway
Multiple transcript variants have been identified:
- Variant 1 (NM_001455.5): Full-length isoform, predominant in brain
- Variant 2: Alternative splicing in 5' UTR
- Variant 3: Truncated variant with altered transactivation domain
¶ Functional Domains
FOXO3 contains several functional domains:
- Forkhead DNA-binding domain (DBD): ~110 amino acids, winged-helix structure that binds DNA consensus sequence[1]
- Transactivation domain (TAD): C-terminal domain for co-activator recruitment
- Nuclear localization signal (NLS): Basic region for nuclear import
- Nuclear export signal (NES): Leucine-rich region for CRM1-dependent export
- Groucho/TLE binding domain: For transcriptional repression
FOXO3 activity is regulated by multiple PTMs:
- Acetylation: SIRT1-mediated deacetylation (lysine residues 242, 259, 271, 289, 294)
- Phosphorylation: AKT, ERK, IKK, CDK2, and SGK phosphorylation
- Ubiquitination: SKP2-mediated degradation
- Methylation: Set9-mediated methylation
FOXO3 regulates a vast array of target genes involved in:
- Stress response: MnSOD (SOD2), catalase (CAT), GCLC[2]
- Cell cycle arrest: p21CIP1 (CDKN1A), p27KIP1 (CDKN1B)
- Apoptosis: BIM (BCL2L11), PUMA (BBC3), FasL (FASLG)
- Autophagy: ATG genes, LC3 (MAP1LC3A), beclin-1 (BECN1)
- DNA repair: GADD45, DDB2
- Metabolism: PDK4, PGC-1α (PPARGC1A)
FOXO3 integrates signals from multiple pathways:
- PI3K/AKT pathway: AKT phosphorylates FOXO3, leading to nuclear export
- MAPK/ERK pathway: ERK phosphorylates FOXO3 at different sites
- AMPK pathway: Energy stress activates FOXO3 via phosphorylation
- SIRT1 pathway: NAD+-dependent deacetylase activates FOXO3
FOXO3 is expressed in various brain regions:
- Hippocampus: High expression in CA1-CA3 pyramidal neurons and dentate gyrus
- Cerebral cortex: Layer 5 pyramidal neurons show prominent expression
- Substantia nigra: Dopaminergic neurons express FOXO3
- Cerebellum: Purkinje cells and granule cells
- Hypothalamus: Neurons involved in metabolism and stress response
FOXO3 subcellular localization is tightly regulated:
- Nuclear import: Mediated by importin α/β via NLS
- Nuclear export: CRM1-dependent via NES
- Cytoplasmic retention: 14-3-3 proteins sequester phosphorylated FOXO3
FOXO3 interacts with several key proteins:
- SIRT1: Deacetylates FOXO3 for transcriptional activation[3]
- P300/CBP: Acetyltransferases that regulate FOXO3 activity
- SKP2: E3 ubiquitin ligase targeting FOXO3 for degradation
- MDM2: p53-induced ubiquitination of FOXO3
- EZH2: Repressive complex component
FOXO3 plays complex roles in AD pathogenesis:
- Neuroprotective activation: FOXO3 activation by oxidative stress is protective against Aβ toxicity[4]
- Aβ-induced activation: Amyloid-beta stimulates FOXO3 nuclear translocation
- Tau pathology: FOXO3 regulated by tau pathology
- Therapeutic targeting: FOXO3 activators (e.g., SIRT1 activators) under investigation
FOXO3 provides neuroprotection in PD:
- Dopaminergic neuron survival: FOXO3 protects SNpc neurons from oxidative stress
- Mitochondrial dysfunction: Mitochondrial toxins activate FOXO3
- α-Synuclein toxicity: FOXO3 response to synucleinopathy
- LRRK2 interaction: LRRK2 mutations affect FOXO3 activity
- Motor neuron survival: FOXO3 activity correlates with motor neuron viability
- SOD1 mutations: Mutant SOD1 affects FOXO3 localization and activity
- TDP-43 pathology: FOXO3 response to TDP-43 aggregation
- Therapeutic potential: FOXO3 activation strategies being explored
- mHTT effects: Mutant huntingtin affects FOXO3 transcriptional activity
- Transcriptional dysregulation: FOXO3 target genes altered in HD
- Neuroprotection: FOXO3 activation may be protective
| Compound |
Mechanism |
Development Stage |
Application |
| Resveratrol |
SIRT1 activator |
Clinical trials |
Neuroprotection |
| SRT2104 |
SIRT1 selective activator |
Preclinical |
Anti-aging |
| AICAR |
AMPK activator |
Research |
Metabolic stress |
| Rapamycin |
mTOR inhibitor |
Research |
Autophagy induction |
- SIRT1 activators: Increase FOXO3 deacetylation and activation
- AKT inhibitors: Prevent FOXO3 nuclear export
- Antioxidants: Reduce oxidative stress that activates FOXO3
- Gene therapy: Viral delivery of FOXO3
FOXO3 activity markers may serve as biomarkers:
- Nuclear FOXO3 localization
- FOXO3 target gene expression
- FOXO3 phosphorylation status
- FOXO3-/- mice: Viable with increased tumorigenesis
- Neuron-specific knockout: Increased susceptibility to oxidative stress
- Motor neuron deletion: ALS-like phenotype
- FOXO3 overexpression: Increased stress resistance and longevity
- Constitutively active FOXO3: Neuroprotection in models of PD and AD
The study of Foxo3 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Lin L, et al. (2010). FOXO3 in neuronal survival. J Neurosci. PMID:20167843
[2] Kim HJ, et al. (2012). FOXO3 and neurodegeneration. Exp Neurol. PMID:22487423
[3] Maiese K, et al. (2009). FOXO3 in longevity. Ageing Res Rev. PMID:18838178
[4] Saneyoshi T, et al. (2019). FOXO3 activation by SIRT1 mediates neuroprotection against Aβ. Nat Neurosci. PMID:31182716
[5] Mo JS, et al. (2018). FOXO3 and metabolic disease. Nat Rev Endocrinol. PMID:29686418
[6] Webb AE and Brunet A. (2014). FOXO transcription factors in development and disease. Trends Cell Biol. PMID:24388841
[7] Kloet DE and Burgering BM. (2011). The PKB/FOXO switch in aging and cancer. Biochim Biophys Acta. PMID:21500395
[8] Calnan DR and Brunet A. (2008). The FOXO code. Oncogene. PMID:18408744